Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 02:00PM GMT
Release Date Price: $14.3 (-2.52%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Coherus this morning at the 40th Annual JPMorgan conference. For the company, we have Denny Lanfear, the President and CEO.

And before I turn it over to Denny, I do want to remind everybody that if you want to ask a question, feel free to use the Ask a Question feature on the website, I'll work those into the Q&A post the presentation.

With that, Denny, happy new year. Thanks for joining us and look forward to the presentation.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Chris, and thank you once again for your kind invitation to this year's JPMorgan conference. Sorry that we couldn't be with you in person.

Let me first apprise you, of course, of the forward-looking statements and direct the audience to the requisite SEC filings with respect to each of the company's products including UDENYCA, YUSIMRY et al. Let me

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot